Forum Πρωτοβάθμιας Φροντίδας Υγείας
ΠΦΥ -Εκπαίδευση => Συζητήσεις πάνω σε ιατρικά θέματα => Μήνυμα ξεκίνησε από: Argirios Argiriou στις 6 Μαρτίου 2026, 20:11:45
-
Έβαλα στο chat gpt την παρακάτω ερώτηση:
- Are glp1 approved for use in Diabetes Mellitus type1?
Και έλαβα την παρακάτω απάντηση:
-
Short answer:
❌ No — GLP-1 receptor agonists are not currently approved for the treatment of Type 1 Diabetes Mellitus (T1DM).
Regulatory approval
Drugs in the GLP-1 receptor agonist class (e.g., semaglutide, liraglutide, dulaglutide) are approved for:
Type 2 diabetes
Obesity / weight management
Some cardiovascular risk reduction indications
However, they are not licensed for glycemic control in Type 1 diabetes.
Regulatory labeling explicitly states that these drugs are not approved for T1DM management, largely because patients with T1DM were excluded from most large randomized trials.
Guideline recommendations
Major guidelines (e.g., ADA) generally state:
Insulin remains the essential therapy in T1DM.
GLP-1 RAs are not recommended as routine treatment for T1DM due to limited safety and efficacy data
Potential concerns include:
Risk of diabetic ketoacidosis
Increased risk of hypoglycemia when combined with insulin
Lack of long-term outcome data in T1DM.
Off-label and research use
There is growing research interest in using GLP-1 agonists as adjunct therapy with insulin in selected T1DM patients.
Studies show possible:
small HbA1c reduction (~0.2%)
weight loss (~3–4 kg)
reduced insulin dose requirements.
Some clinicians may prescribe them off-label, particularly in T1DM patients with:
obesity
insulin resistance
high insulin requirements
But this is not standard practice and requires specialist supervision.